A link between histone deacetylases (HDACs) and intestinal inflammation has been established. HDAC inhibitors that target gut-selective inflammatory pathways represent a potential new therapeutic strategy in patients with refractory inflammatory bowel diseases (IBD).

Felice, C., Lewis, A., Armuzzi, A., Lindsay, J., Silver, A., Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases, <<ALIMENTARY PHARMACOLOGY & THERAPEUTICS>>, 2015; 41 (1): 26-38. [doi:10.1111/apt.13008] [http://hdl.handle.net/10807/64558]

Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases

Armuzzi, Alessandro;
2014

Abstract

A link between histone deacetylases (HDACs) and intestinal inflammation has been established. HDAC inhibitors that target gut-selective inflammatory pathways represent a potential new therapeutic strategy in patients with refractory inflammatory bowel diseases (IBD).
2014
Inglese
Felice, C., Lewis, A., Armuzzi, A., Lindsay, J., Silver, A., Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases, <<ALIMENTARY PHARMACOLOGY & THERAPEUTICS>>, 2015; 41 (1): 26-38. [doi:10.1111/apt.13008] [http://hdl.handle.net/10807/64558]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/64558
Citazioni
  • ???jsp.display-item.citation.pmc??? 39
  • Scopus 93
  • ???jsp.display-item.citation.isi??? 89
social impact